HK1102423A1 - Muscarinic acetylcholine receptor antagonists - Google Patents

Muscarinic acetylcholine receptor antagonists

Info

Publication number
HK1102423A1
HK1102423A1 HK07106891.0A HK07106891A HK1102423A1 HK 1102423 A1 HK1102423 A1 HK 1102423A1 HK 07106891 A HK07106891 A HK 07106891A HK 1102423 A1 HK1102423 A1 HK 1102423A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
acetylcholine receptor
muscarinic acetylcholine
muscarinic
antagonists
Prior art date
Application number
HK07106891.0A
Other languages
English (en)
Inventor
Dramane I Laine
Michael R Palovich
Brent W Mccleland
Christopher E Neipp
Sonia M Thomas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1102423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1102423A1 publication Critical patent/HK1102423A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
HK07106891.0A 2004-04-27 2007-06-27 Muscarinic acetylcholine receptor antagonists HK1102423A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (1)

Publication Number Publication Date
HK1102423A1 true HK1102423A1 (en) 2007-11-23

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106891.0A HK1102423A1 (en) 2004-04-27 2007-06-27 Muscarinic acetylcholine receptor antagonists

Country Status (38)

Country Link
US (9) US7498440B2 (uk)
EP (3) EP3111936A1 (uk)
JP (2) JP5014121B2 (uk)
KR (2) KR101037026B1 (uk)
CN (2) CN1976701A (uk)
AP (1) AP2213A (uk)
AR (1) AR050902A1 (uk)
AU (1) AU2005237576B2 (uk)
BE (1) BE2014C063I2 (uk)
BR (1) BRPI0510170B8 (uk)
CA (2) CA2755954C (uk)
CY (3) CY1113196T1 (uk)
DK (2) DK2570128T3 (uk)
EA (2) EA021994B1 (uk)
EC (1) ECSP066940A (uk)
ES (2) ES2600405T3 (uk)
HK (1) HK1102423A1 (uk)
HR (2) HRP20120832T1 (uk)
HU (2) HUE031304T2 (uk)
IL (1) IL178152A (uk)
LT (1) LT2570128T (uk)
LU (1) LU92565I2 (uk)
MA (1) MA28631B1 (uk)
MX (1) MXPA06012405A (uk)
MY (1) MY144753A (uk)
NL (1) NL300694I1 (uk)
NO (3) NO338959B1 (uk)
NZ (1) NZ549997A (uk)
PE (1) PE20060259A1 (uk)
PL (2) PL1740177T3 (uk)
PT (2) PT1740177E (uk)
SG (1) SG186597A1 (uk)
SI (2) SI2570128T1 (uk)
TW (1) TWI363759B (uk)
UA (1) UA95768C2 (uk)
UY (1) UY28871A1 (uk)
WO (1) WO2005104745A2 (uk)
ZA (1) ZA200608565B (uk)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
US7507747B2 (en) * 2003-10-17 2009-03-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1732547B1 (en) * 2004-04-05 2008-08-20 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7943651B2 (en) 2006-04-20 2011-05-17 Glaxo Group Limited Compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
CL2009000250A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
TW200946525A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
PL2400950T3 (pl) 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
KR101679642B1 (ko) 2009-04-30 2016-11-25 글락소 그룹 리미티드 Ｐｉ3­키나아제 억제제로서 옥사졸 치환된 인다졸
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
ES2655083T3 (es) * 2010-01-28 2018-02-16 Theron Pharmaceuticals, Inc. Derivados de 7-azoniabiciclo [2.2.1]heptano, métodos de producción, y usos farmacéuticos de estos
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
MA34326B1 (fr) * 2010-06-22 2013-06-01 Chiesi Farma Spa Formulation de poudre sèche comprenant un médicament antimuscarinique
PT2614058E (pt) 2010-09-08 2015-10-27 Glaxosmithkline Ip Dev Ltd Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CA2838031A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
CA2838030A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
ES2678697T3 (es) * 2012-08-15 2018-08-16 Glaxo Group Limited Proceso químico
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
TR201906532T4 (tr) 2013-07-13 2019-05-21 Beijing Shuobai Pharmaceutical Co Ltd Kinin bileşikleri ve optik izomerleri, hazırlanış yöntemleri ve tıbbi kullanımları.
KR20160034920A (ko) * 2013-07-30 2016-03-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 과도한 발한의 치료를 위한 국소 조성물 및 그의 사용 방법
AU2014336251A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
US20160256466A1 (en) 2013-10-17 2016-09-08 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
EP3650019B8 (en) 2014-05-28 2023-10-11 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
CA2965590A1 (en) 2014-11-03 2016-05-12 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
WO2021218833A1 (zh) * 2020-04-26 2021-11-04 北京硕佰医药科技有限责任公司 一种m受体拮抗剂的晶体、制备方法及其应用
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (uk) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
DK163640C (da) 1985-07-30 1992-08-17 Glaxo Group Ltd Apparat til administrering af medikamenter
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) * 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EE05404B1 (et) * 2000-12-28 2011-04-15 Almirall Prodesfarma Ag Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
US7361668B2 (en) * 2001-10-17 2008-04-22 Ucb, S.A. Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2003042210A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
US7232841B2 (en) 2003-04-07 2007-06-19 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20050711A1 (es) 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
UY28417A1 (es) 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
DE602004030930D1 (de) 2003-10-14 2011-02-17 Glaxo Group Ltd Muscarinische acetylcholin-rezeptor-antagonisten
US7507747B2 (en) 2003-10-17 2009-03-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
EP1685118B1 (en) * 2003-11-21 2009-07-08 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1751089A4 (en) 2004-03-11 2010-03-10 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20070185088A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen M3 muscarinic acetylchoine receptor antagonists
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185090A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR050902A1 (es) * 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
JP2007537261A (ja) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US7579345B2 (en) 2004-05-28 2009-08-25 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
US20090076061A1 (en) 2004-08-06 2009-03-19 Jakob Busch-Petersen Muscarinic acetycholine receptor antagonists
EP1824483A4 (en) 2004-10-29 2009-11-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
US20080275079A1 (en) 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
EP2570128A1 (en) 2013-03-20
DK1740177T3 (da) 2012-10-29
US20150238470A1 (en) 2015-08-27
MY144753A (en) 2011-10-31
MA28631B1 (fr) 2007-06-01
US8853404B2 (en) 2014-10-07
US20140371264A1 (en) 2014-12-18
US9045469B2 (en) 2015-06-02
JP2007534769A (ja) 2007-11-29
CN1976701A (zh) 2007-06-06
WO2005104745A3 (en) 2006-08-03
IL178152A (en) 2011-05-31
SI2570128T1 (sl) 2016-11-30
US9144571B2 (en) 2015-09-29
CA2755954A1 (en) 2005-11-10
CA2564742A1 (en) 2005-11-10
NO338959B1 (no) 2016-11-07
US7498440B2 (en) 2009-03-03
KR20070015412A (ko) 2007-02-02
NO2017018I1 (no) 2017-05-04
NL300694I2 (uk) 2015-12-29
CY2014043I2 (el) 2015-12-09
TWI363759B (en) 2012-05-11
HUE031304T2 (hu) 2017-07-28
EP1740177B1 (en) 2012-08-08
CY2014043I1 (el) 2015-12-09
BRPI0510170B8 (pt) 2021-05-25
US20160002220A1 (en) 2016-01-07
PL2570128T3 (pl) 2017-09-29
US20090124653A1 (en) 2009-05-14
EA200601991A1 (ru) 2007-02-27
NO20065417L (no) 2006-12-29
US8183257B2 (en) 2012-05-22
EP3111936A1 (en) 2017-01-04
HRP20161385T1 (hr) 2016-12-02
JP5398871B2 (ja) 2014-01-29
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
MXPA06012405A (es) 2007-01-17
ES2392848T4 (es) 2014-10-01
US20120157491A1 (en) 2012-06-21
BRPI0510170A (pt) 2007-10-02
EP2570128B1 (en) 2016-08-10
LU92565I9 (uk) 2019-01-17
US20070185155A1 (en) 2007-08-09
AR050902A1 (es) 2006-12-06
WO2005104745A2 (en) 2005-11-10
EA201100019A1 (ru) 2011-12-30
KR101037026B1 (ko) 2011-05-25
KR101152032B1 (ko) 2012-06-11
US8309572B2 (en) 2012-11-13
AP2006003746A0 (en) 2006-10-31
AU2005237576A1 (en) 2005-11-10
NO2017017I1 (no) 2017-05-04
ES2392848T3 (es) 2012-12-14
TW200605887A (en) 2006-02-16
CA2564742C (en) 2012-01-10
EP1740177A2 (en) 2007-01-10
ZA200608565B (en) 2019-12-18
KR20110010841A (ko) 2011-02-07
CY1113196T1 (el) 2015-12-09
DK2570128T3 (en) 2016-11-07
LU92565I2 (fr) 2014-12-02
ECSP066940A (es) 2006-12-20
JP2012162559A (ja) 2012-08-30
EA015033B1 (ru) 2011-04-29
AU2005237576B2 (en) 2012-01-12
ES2600405T3 (es) 2017-02-08
HRP20120832T1 (hr) 2012-11-30
NZ549997A (en) 2010-10-29
BRPI0510170B1 (pt) 2018-12-18
EP1740177A4 (en) 2010-05-05
UA95768C2 (uk) 2011-09-12
SI1740177T1 (sl) 2012-12-31
CN102040602A (zh) 2011-05-04
EA021994B1 (ru) 2015-10-30
AP2213A (en) 2011-03-01
NL300694I1 (uk) 2015-12-29
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
UY28871A1 (es) 2005-11-30
PL1740177T3 (pl) 2012-12-31
LT2570128T (lt) 2016-10-10
PT2570128T (pt) 2016-10-07
PT1740177E (pt) 2012-11-02
CY1118082T1 (el) 2017-06-28
CA2755954C (en) 2014-02-18
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
SG186597A1 (en) 2013-01-30
US20130030015A1 (en) 2013-01-31
IL178152A0 (en) 2006-12-31
HUS1400053I1 (hu) 2017-07-28
US7488827B2 (en) 2009-02-10
BE2014C063I2 (uk) 2024-08-08

Similar Documents

Publication Publication Date Title
HUS1400053I1 (hu) Muszkarin acetilkolin receptor antagonisták
IL176775A0 (en) Muscarinic acetylcholine receptor antagonists
IL188112A0 (en) Muscarinic acetylcholine receptor antagonists
EP1749012A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1824483A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1937068A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1725240A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
IL172911A0 (en) Muscarinic acetylcholine receptor antagonists
EP1725236A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
IL172912A0 (en) Muscarinic acetylcholine receptor antagonists
EP1957075A4 (en) NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
SI1682142T1 (sl) Antagonisti M3 muskarinskega acetilholinskega receptorja
EP1765339A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1827439A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
IL174846A0 (en) Muscarinic acetylcholine receptor antagonists
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
EP1725238A4 (en) ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
EP1937267A4 (en) M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP1937230A4 (en) M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP1781104A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1781103A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1751089A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725241A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC M3 RECEPTOR
EP1725564A4 (en) ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
AP2008004537A0 (en) Muscarinic receptor antagonists